Cutera is a medical devices business based in the US. Cutera shares (CUTR) are listed on the NASDAQ and all prices are listed in US Dollars. Cutera employs 430 staff and has a trailing 12-month revenue of around $196.6 million.
Paid non-client promotion. Finder does not invest money with providers on this page. If a brand is a referral partner, we're paid when you click or tap through to, open an account with or provide your contact information to the provider. Partnerships are not a recommendation for you to invest with any one company. Learn more about how we make money.
Finder is not an advisor or brokerage service. Information on this page is for educational purposes only and not a recommendation to invest with any one company, trade specific stocks or fund specific investments. All editorial opinions are our own.
| Latest market close | $1.40 |
|---|---|
| 52-week range | $1.28 - $21.41 |
| 50-day moving average | $1.84 |
| 200-day moving average | $2.46 |
| Wall St. target price | $6.33 |
| PE ratio | N/A |
| Dividend yield | N/A (0%) |
| Earnings per share (TTM) | $-7.91 |
The technical analysis gauge below displays real-time ratings for the timeframes you select. This is not a recommendation, however. It represents a technical analysis based on the most popular technical indicators: Moving Averages, Oscillators and Pivots. Finder might not concur and takes no responsibility.
This chart is not advice or a guarantee of success. Rather, it gauges the real-time recommendations of three popular technical indicators: moving averages, oscillators and pivots. Finder is not responsible for how your stock performs.
Historical closes compared with the close of $1.4 from 2024-07-25
| 1 week (2024-07-19) | -11.95% |
|---|---|
| 1 month (2024-06-27) | -4.11% |
| 3 months (2024-04-26) | -33.96% |
| 6 months (2024-01-26) | -52.05% |
| 1 year (2023-07-27) | -92.33% |
|---|---|
| 2 years (2022-07-27) | -96.82% |
| 3 years (2021-07-27) | 49.95 |
| 5 years (2019-07-26) | 25.55 |
Valuing Cutera stock is incredibly difficult, and any metric has to be viewed as part of a bigger picture of Cutera's overall performance. However, analysts commonly use some key metrics to help gauge the value of a stock.
Cutera's "price/earnings-to-growth ratio" can be calculated by dividing its P/E ratio by its growth – to give 9.05. A low ratio can be interpreted as meaning the shares offer better value, while a higher ratio can be interpreted as meaning the shares offer worse value.
The PEG ratio provides a broader view than just the P/E ratio, as it gives more insight into Cutera's future profitability. By accounting for growth, it could also help you if you're comparing the share prices of multiple high-growth companies.
| Revenue TTM | $196.6 million |
|---|---|
| Gross profit TTM | $139.8 million |
| Return on assets TTM | -22.64% |
| Return on equity TTM | -4447.26% |
| Profit margin | -80.13% |
| Book value | $-9.60 |
| Market Capitalization | $32.2 million |
TTM: trailing 12 months
We're not expecting Cutera to pay a dividend over the next 12 months.
Over the last 12 months, Cutera's shares have ranged in value from as little as $1.28 up to $21.4122. A popular way to gauge a stock's volatility is its "beta".
Beta is a measure of a share's volatility in relation to the market. The market (NASDAQ average) beta is 1, while Cutera's is 1.322. This would suggest that Cutera's shares are more volatile than the average for this exchange and represent, relatively-speaking, a higher risk (but potentially also market-beating returns).
Cutera, Inc. provides aesthetic and dermatology solutions for medical practitioners worldwide. It develops, manufactures, and markets energy-based product platforms for medical practitioners; and distributes third-party manufactured skincare products. The company provides AviClear for the treatment of mild, moderate, and severe inflammatory acne vulgaris; Secret PRO, a device that utilizes fractional CO2 for skin resurfacing and radio frequency (RF) microneedling for skin revitalization; truFlex, a bio-electrical muscle stimulation device designs to strengthen, firm and tone the abdomen, buttocks, and thighs; and excel V/V+, a vascular and benign pigmented lesion treatment platform. It also offers truSculpt, a high-powered radio frequency system designed for circumferential reduction, lipolysis, and deep tissue heating and treat all skin types; Secret RF, a fractional RF microneedling device that delivers heat into the deeper layers of the skin using controlled RF energy; and Enlighten SR/III, a laser platform with a dual wavelength for multi-colored tattoo removal, and the treatment of benign pigmented lesions and acne scars. In addition, the company provides Excel HR, a hair removal solution for all skin types; xeo, a multi-application platform for the removal of unwanted hair, treatment of vascular lesions, and skin revitalization by treating discoloration, fine lines, and laxity; and Secret DUO, two dual non-ablative fractional technologies that can be used individually or in combination to target a variety of aesthetic concerns and skin conditions on all skin types with little to no downtime. Further, it offers its products through direct sales and services, and network of distributors and direct international sales.
Trade commission-free stocks and ETFs with Opto, and stay ahead by spotting emerging trends through thematic investing.
Check out our picks of the best paper trading platforms to practice trading and investing with fake money.
Learn the basics of put options: what they are, how they work and a few examples.
Check out our picks for the brokers with the best cash sweep rates on uninvested cash.
These are the best day trading platforms, according to Finder’s comprehensive analysis.
Explore the best bonuses for opening a new brokerage account.
Looking for a discount broker like Webull that offers something different? Here are some of the top alternatives to consider.
What you need to know about investing in the leading indicator for the overall US stock market.
Check out our 7 ideas for how to invest $10K to maximize your money.
Check out the best-performing ETFs so far in 2024.